Patents Examined by Adam C Milligan
-
Patent number: 11964014Abstract: Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.Type: GrantFiled: August 8, 2023Date of Patent: April 23, 2024Assignee: THE UNIVERSITY OF MONTANAInventors: Helene Bazin-Lee, David Burkhart, Jay Evans
-
Patent number: 11931340Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.Type: GrantFiled: October 7, 2021Date of Patent: March 19, 2024Assignee: BioXcel Therapeutics, Inc.Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
-
Patent number: 11890380Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.Type: GrantFiled: March 28, 2023Date of Patent: February 6, 2024Assignee: KING ABDULAZIZ UNIVERSITYInventors: Omar D. Al-hejaili, Khalid M. El-Say, Tarek A. Ahmed, Hossam S. El-Sawy, Fathy I. Abd-Allah
-
Patent number: 11882858Abstract: A skin whitening composition includes ?-mangostin or a cosmetically acceptable salt thereof as an effective ingredient. ?-Mangostin represented by Chemical Formula 1 suppresses the expression of tyrosinase and TRP-1 (tyrosinase-related protein-1) and induces autophagy of a melasosome. As such, it was confirmed that the ?-mangostin not only suppresses melanin production but also exhibits the effect of removing previously formed melanin. Accordingly, the ?-mangostin can be advantageously used as a functional material for skin whitening and skin lightening.Type: GrantFiled: September 20, 2016Date of Patent: January 30, 2024Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITYInventors: Kwang Dong Kim, Ji Yun Yoo, Hyung Won Ryu, Soojong Park, Kiwon Lee, Ki Hun Park, Sangseok Oh
-
Patent number: 11857654Abstract: Embodiments relate to a composition comprising nanohydroxyapatite (NHAP) in an amount about 0.5 wt. % to about 50 wt. % of the composition having a particle size in a range of about 20-100 nm, an abrasive, a sweetener, and a natural oil, wherein the composition does not contain glycerin and fluoride, wherein the composition is alkaline and a dental product, and wherein the natural oil is a plant product.Type: GrantFiled: October 8, 2021Date of Patent: January 2, 2024Inventor: Sonia Gupta
-
Patent number: 11859151Abstract: Described herein is a method of using as perfuming ingredients, e.g. to impart odor notes of the fruity, fruity-exotic types, cyclopentanone compounds of formula in a form of any one of its stereoisomers or a mixture thereof, and wherein n represents 1 or 2.Type: GrantFiled: October 14, 2019Date of Patent: January 2, 2024Assignee: FIRMENICH SAInventors: Julien Coulomb, Edouard Demole
-
Patent number: 11839604Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.Type: GrantFiled: December 29, 2017Date of Patent: December 12, 2023Assignee: Bioxcel Therapeutics, Inc.Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
-
Patent number: 11793786Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.Type: GrantFiled: April 12, 2021Date of Patent: October 24, 2023Assignee: Neurelis, Inc.Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
-
Patent number: 11786508Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.Type: GrantFiled: November 18, 2022Date of Patent: October 17, 2023Assignee: BioXcel Therapeutics, Inc.Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
-
Patent number: 11759405Abstract: Provided is an oral composition containing particles that have properties to seal dentinal tubules and excellent adhesion properties in dentinal tubules. Specifically, provided is an oral composition containing hydroxyapatite particles, wherein the hydroxyapatite particles have a ratio of a diffraction peak intensity around 2?=32° to a diffraction peak intensity around 2?=26° of 0.8 to 1.6 in an x-ray powder diffraction pattern as measured with CuK? characteristic X-rays.Type: GrantFiled: December 27, 2019Date of Patent: September 19, 2023Assignee: SUNSTAR SUISSE SAInventors: Taku Ideue, Akihiko Komine, Ryotaro Nishioka, Shuhei Ishii
-
Patent number: 11744803Abstract: The invention relates to delivery systems that allow for the pulsatile release of a substance, such as a drug, in response to a change in pH. More specifically, it relates to drug administration to the GI tract, in particular to site-specific intestinal drug delivery via the oral route. Provided is a pH-controlled pulsatile release system (PPRS) comprising a core surrounded by a coating layer, wherein said core comprises an active substance and wherein said coating layer comprises a pH-sensitive coating material wherein a swellable agent is embedded. Said swellable agent is capable of taking up at least 1.1 times, preferably at least 5 times, more preferably at least 10 times its weight in water. Also provided is a pharmaceutical composition comprising a PPRS, in particular a colon-specific PPRS.Type: GrantFiled: July 29, 2005Date of Patent: September 5, 2023Assignee: Stichting Groningen Centre for Drug ReseInventors: Reinout Cornelus Andreas Schellekens, Henderik Willem Frijlink
-
Patent number: 11737969Abstract: Method for remineralizing teeth or increasing hardness of tooth enamel by application of Brazilian green propolis oil or its components.Type: GrantFiled: February 28, 2023Date of Patent: August 29, 2023Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: Saqib Ali, Imran Farooq, Amr Bugshan, Intisar Ahmad Siddiqui, Khalifa S. Al-Khalifa, Mohammed Taha Ali Al-Hariri
-
Patent number: 11690791Abstract: An oral care composition having a soluble zinc polyphosphate complex made by combining ingredients including a zinc salt, a plurality of long chain polyphosphates having 6 or more phosphate polymer units, and a solvent, the relative amount of organic zinc salt and long chain polyphosphates provides a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of treating a subject suffering from dentinal sensitivity applying the oral care composition to the teeth and gums of the subject.Type: GrantFiled: December 26, 2014Date of Patent: July 4, 2023Assignee: Colgate-Palmolive CompanyInventors: Shiri Nawrocki, Viktor Dubovoy, Long Pan, Baohua Qiao, Gregory Szewczyk, Ravi Subramanyam
-
Patent number: 11648226Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).Type: GrantFiled: September 21, 2020Date of Patent: May 16, 2023Assignee: Indiana University Research and Technology CorporationInventors: Mark R. Kelley, Melissa L. Fishel
-
Patent number: 11648205Abstract: A buccal tablet formulation has a polyvinylpyrrolidone K-90 as a solid dispersion polymer, a hydroxypropyl methylcellulose as a mucoadhesive polymer, a sodium deoxycholate as mucopenetration enhancer, a porous silicon dioxide (e.g., FujiSil), mannitol, and avanafil. The ratio of PVP K-90 to AVA is approximately 2:1 (e.g., 2.3:1 to 1.7:1) in the tablet. Methods of making the buccal tablet with enhanced bioavailability and prolonged duration and methods of using the formulation for the treatment of erectile dysfunction are also provided.Type: GrantFiled: October 14, 2022Date of Patent: May 16, 2023Assignee: KING ABDULAZIZ UNIVERSITYInventors: Omar D. Al-hejaili, Khalid M. El-Say, Tarek A. Ahmed, Hossam S. El-Sawy, Fathy I. Abd-Allah
-
Patent number: 11633502Abstract: Described herein are liposome-based nanocarriers that selectively target bone marrow, minimize tumor delivery, and maintain high drug concentrations in bone marrow when compared to conventional systemic delivery. The composition of the liposome-based nanocarriers may also be tuned to selectively target lymph nodes and other reticuloendothelial system organs (e.g., spleen, e.g., liver). Also described herein are methods of imaging and mapping the bone marrow and/or other reticuloendothelial system organs using the described liposome-based nanocarriers. These methods provide high resolution non-invasive and quantitative imaging via PET, which offers advantages over conventional imaging/tracking methods. Furthermore, in certain embodiments, the liposome-based carriers are used to stabilize and deliver radioprotectant/free radical scavenger drugs to the bone marrow, thereby protecting the bone marrow from subsequent radiation exposure, thereby limiting the adverse impact of radiation exposure on the individual.Type: GrantFiled: March 7, 2017Date of Patent: April 25, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: Naga Vara Kishore Pillarsetty, Steven M. Larson, Sang-gyu Lee
-
Patent number: 11623010Abstract: The present invention relates to the use of a pharmaceutical carrier in the preparation of anti-diabetic pharmaceutical composition. In particular, the present invention relates to the use of a pharmaceutical carrier in the preparation of anti-diabetic pharmaceutical composition, wherein the pharmaceutical carrier consists of well-mixed sesame oil and beeswax, the anti-diabetic pharmaceutical composition comprises oryzanol and berberine hydrochloride as active ingredients; wherein the oryzanol is present in an amount of 1-5% by weight, the berberine hydrochloride is present in an amount of 5-50% by weight, the beeswax is present in an amount of 1-20% by weight, and the sesame oil is present in an amount of 40-85% by weight, relative to the total weight of the pharmaceutical composition.Type: GrantFiled: August 27, 2019Date of Patent: April 11, 2023Assignees: BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD.Inventor: Li Li
-
Patent number: 11617369Abstract: This invention relates to antimicrobial gallium compounds, and to monomers containing gallium complex moieties that can be used in oral care products and dental materials, and which can reduce or eliminate dental caries and bacterial or fungal infections associated with medical and dental devices.Type: GrantFiled: August 26, 2020Date of Patent: April 4, 2023Assignee: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventor: Xiaoming Xu
-
Patent number: 11607381Abstract: Method for remineralizing teeth or increasing hardness of tooth enamel by application of Brazilian green propolis oil or its components.Type: GrantFiled: April 19, 2021Date of Patent: March 21, 2023Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: Saqib Ali, Imran Farooq, Amr Bugshan, Intisar Ahmad Siddiqui, Khalifa S. Al-Khalifa, Mohammed Taha Ali Al-Hariri
-
Patent number: 11566110Abstract: Provided are a self-assembled amino acid supramolecular polymer and a preparation method therefor. Further provided is an application of the self-assembled amino acid supramolecular polymer in the fields of daily chemical, agricultural, and pharmaceutical industries. The provided self-assembled amino acid supramolecular polymer has good performance, and has obvious effects in aspects such as bacteriostasis, pesticide removal, and odor elimination. The provided self-assembled amino acid supramolecular polymer is applicable to toothpastes, skin care compositions, laundry detergents, soaps, washing powders, detergents, masks, etc.Type: GrantFiled: June 3, 2019Date of Patent: January 31, 2023Assignee: SUZHOU OULIT BIOPHARM CO., LTDInventor: Jian Zhang